Navigation Links
Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
Date:3/10/2009

al sleep time (p<0.001), decreased total time awake (p<0.001) and improved sleep efficiency (calculated by the proportion of the time spent sleeping while in bed, p<0.001).

Intra-Cellular Therapies believes that ITI-007 promotes natural, restorative sleep. In particular, ITI-007 did not cause rebound insomnia during early morning hours and did not suppress rapid eye movement (REM) sleep as some hypnotic agents do. ITI-007 significantly and dose-dependently increased the percent of SWS early in the night (p=0.022 for the first quarter of the night, p=0.029 for the second quarter of the night). Late in the night, towards morning, ITI-007 increased the percent of Stage 2 sleep (p=0.048 for the third quarter of the night, p=0.004 for the fourth quarter of the night). ITI-007 did not affect total duration of REM sleep (p=0.124) and ITI-007 did not affect latency to the first episode of REM (p=0.143). As predicted by its mechanism, ITI-007 did not affect latency to persistent sleep (p=0.455). Overall, the increases in SWS and Stage 2 sleep came at the expense of decreased percent time spent awake or drowsy (Stage 1 sleep, p<0.001). This was especially reflected by the ability of ITI-007 to decrease percent time spent awake or drowsy in the fourth quarter of the night compared to placebo (p=0.002), a time when other hypnotics tend to cause rebound increases in early morning wakefulness.

PHASE II RESULTS FOR ITI-007

                                                                  Dose-
                                                                Response
                                                                  Trend
    Polysomnography                                             Analysis
    Outcome Measure      Mean Change from Baseline (min)         p-value
                                             ITI-007
                       Placebo      1 mg      5 mg     10 mg

    SWS  
'/>"/>
SOURCE Intra-Cellular Therapies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
2. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
3. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
4. MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies
5. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
6. Old and new therapies combine to tackle atherosclerosis
7. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
8. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
9. 18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto
10. Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Pennsylvanie, 18 septembre 2014 Mapi, ... en 1974, a été depuis 40 ans ... évaluations cliniques traditionnelles par des évaluations recentrées ... sur les impacts économiques des traitements. ... A cours d,une récente conférence ...
(Date:9/18/2014)... expensive. Now a team led by an engineer at ... designs that will let scientists slash the cost of ... , Syringe pumps are used to dispatch precise amounts ... in a reaction. They can also cost hundreds or ... team of Michigan Tech students published the library of ...
(Date:9/18/2014)... Silicon-valley Electronic Data Capture (EDC) provider ... , the latest addition to Clinovo’s CRO Partnership Program. ... (CRO) Program, Clinovo further expands its global reach to ... training, we are now able to build studies on ... can also rely on Clinovo to fully support the ...
(Date:9/17/2014)... 17, 2014 A long-term retrospective study ... irradiation (APBI) via interstitial brachytherapy suggests that women ... nodes could be suitable to receive the treatment. ... place these patients in the "unsuitable" category for ... ASTRO meeting, Beaumont Health System,s Peter Y. ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Doing science just got cheaper -- and faster 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4
... DUBLIN, Ireland, January 9 Azur Pharma ... the exclusive U.S. marketing rights,for Niravam(R) (alprazolam ... Kemstro(TM) (baclofen,orally disintegrating tablets) and Fluxid(TM) (famotidine ... terms were not,disclosed. , ...
... The IN VIVO Blog , which provides news, insights and ... a Deal of the Year for 2008 -- ... than 2,500 reader votes were cast in this inaugural competition, ... the 13 nominees selected by The IN VIVO Blog,s writers ...
... MATK ) announced today that it will be ... The conference is being held January 14-15, 2009 at ... Point, California. Peter L. Buzy, Chief Financial Officer, and ... 2009 at 1:25 PM PT.A live audio webcast of Martek,s ...
Cached Biology Technology:Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB 2The IN VIVO Blog Selects First Annual 'Deal of the Year' 2
(Date:9/18/2014)... Elsevier, a world-leading provider of scientific, technical and ... Research Management Society (ARMS), recognized the academic research ... Scopus Young Researcher of the Year Awards. , ... National Convention Centre and in conjunction with the ... representing Australia,s and New Zealand,s scientific community. Guest ...
(Date:9/18/2014)... entire lives nestling in the protective tentacles of host ... sometimes travel hundreds of kilometres across the open ocean. ... has been predicted, this is the first time that ... has been observed. , Dr Steve Simpson, Senior Lecturer ... of Exeter, and colleagues from the Australian Research Council ...
(Date:9/17/2014)... EC-FP5 four-year project, delivering its first release in 2004. ... in several EC projects, as a part of the ... BON), to increase the general awareness of the work ... dissemination of the Fauna Europaea results, the ... e-Publishing tools to prepare data papers for all 56 ...
Breaking Biology News(10 mins):Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2
... Wash. -- A new study reveals how pollution causes ... Appearing in the Proceedings of the National Academy ... long-standing debate and reveal how pollution plays into climate ... the accuracy of weather and climate models. Researchers ...
... that protect it from insect damage has been grown in the ... are derived from a bacterium called Bacillus thuringiensis , these ... has been highly effective against the European corn borer, it has ... documented to show resistance to the Bt proteins. In a new ...
... impairment is a transitional stage between normal aging ... this transformation have yet to be studied. Dr. ... Technology, China constructed brain networks using resting-state functional ... (normal controls, patients with early mild cognitive impairment, ...
Cached Biology News:The lingering clouds 2The lingering clouds 3Scientists offer recommendations for delaying resistance to Bt corn in western corn rootworm 2